New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 7, 2014
08:19 EDTONVOOrganovo reports Q3 EPS (7c) vs. (20c) a year ago
Reports Q3 revenue $135K, one estimate $180K. The company said its decrease in revenue from prior year levels reflects declining activity under an existing collaborative agreement and the conclusion of a previous collaborative research agreement during the quarter, partially offset by increasing revenue contributions from three recently signed agreements. Organovo is a development stage company, and does not expect product-based revenue until the commercial release of its liver toxicity assay product, currently planned to be before the end of November.
News For ONVO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 18, 2014
12:08 EDTONVOOn The Fly: Midday Wrap
Subscribe for More Information
08:09 EDTONVOOrganovo announces commercial release of exVive3D liver tissue
Organovo Holdings announced the full commercial release of the exVive3D Human Liver Tissue for preclinical drug discovery testing. Initially, clients will be able to access the technology through Organovo's contract research services program. This model is intended to provide human-specific data to aid in the prediction of liver tissue toxicity or ADME outcomes in later stage preclinical drug discovery programs.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use